Biocytogen and Acepodia Join Forces to Advance Bispecific Antibody and Dual-Payload ADCs for Treating Complex Tumors
Biocytogen (HKEX: 02315) and Acepodia (6976:TT), today announced a groundbreaking strategic partnership to jointly assess a dual-payload bispecific antibody-drug conjugate (BsAD2C) program.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250107874851/en/
Biocytogen and Acepodia Join Forces to Advance Bispecific Antibody and Dual-Payload ADCs for Treating Complex Tumors. (Graphic: Business Wire)
This collaboration combines Biocytogen’s RenLite® platform with Acepodia’s Antibody-Dual-Drugs Conjugation (AD2C) technology to tackle some of the toughest challenges in oncology—tumor heterogeneity and drug resistance. This novel approach aims to address these complexities by utilizing dual-payloads that target multiple therapeutic or disease pathways. These payloads are delivered with bispecific antibodies that enable enhanced precision and functionality.
As part of the strategic partnership, Biocytogen will provide a bispecific antibody derived from its proprietary RenLite® platform, which is designed to produce fully human bispecific antibodies with unique binding properties. To this antibody, Acepodia will integrate two different payloads using its Antibody-Dual-Drugs Conjugation (AD2C) platform. This platform enables site-selective conjugation of multiple payloads to an antibody using bio-orthogonal click chemistry with no required antibody engineering, maintaining antibody integrity and binding capacity, and allowing strategic and precise control over the Drug-to-Antibody Ratio (DAR) for optimal potency and safety.
“We are thrilled to partner with the Acepodia team who brings deep expertise in bio-orthogonal click chemistry and the unique opportunity to combine our RenLite® bispecific antibodies with site-selective dual-payload conjugates,” said Dr. Yuelei Shen, President and CEO of Biocytogen. “We look forward to bridging our platforms to explore the therapeutic potential of highly potent BsADCs.”
“Biocytogen’s superior bispecific antibodies and highly collaborative team make them an ideal partner for advancing our AD2C payload platform,” said Sonny Hsiao, Ph.D., Co-Founder and CEO of Acepodia. “This partnership redefines the possibilities of ADC design, with the potential to deliver breakthrough therapies to patients in desperate need of new options.”
This strategic partnership underscores the commitment of both companies to addressing the critical unmet needs in ADC drug development for solid tumors, paving the way for innovative therapies that improve patient outcomes
About Biocytogen
Biocytogen (HKEX: 02315) is a global biotechnology company that drives the research and development of novel antibody-based drugs with innovative technologies. Founded on gene editing technology, Biocytogen leverages genetically engineered proprietary RenMice® (RenMab™/ RenLite®/ RenNano®/ RenTCR-mimic™ ) platforms for fully human monoclonal/bispecific/multispecific antibody discovery, bispecific antibody-drug conjugate discovery, nanobody discovery and TCR-mimic antibody discovery, and has established a sub-brand, RenBiologics™, to explore global partnerships for an off-the-shelf library of >400,000 fully human antibody sequences against approximately 1000 targets for worldwide collaboration. As of June 30, 2024, approximately 150 therapeutic antibody and multiple clinical asset co-development/out-licensing/transfer agreements and nearly 50 target-nominated RenMice® licensing projects have been established around the globe, including several partnerships with multinational pharmaceutical companies (MNCs). Biocytogen pioneered the generation of drug target knock-in humanized models for preclinical research, and currently provides a few thousand off-the-shelf animal and cell models under the company's sub-brand, BioMice™, along with preclinical pharmacology and gene-editing services for clients worldwide. Headquartered in Beijing, Biocytogen has branches in China (Haimen Jiangsu, Shanghai), USA (Boston, San Francisco), and Germany (Heidelberg). For more information, please visit http://en.biocytogen.com.cn.
About Acepodia
Acepodia is transforming cancer and autoimmune disease treatment with first-in-class immune cell engagers that deliver enhanced and targeted potency through multiple conjugation platforms. Leveraging a family of bio-orthogonal click chemistry approaches originating from Nobel Prize laureate Carolyn Bertozzi’s lab, Acepodia’s platforms are designed to improve safety and offer broad applicability across hematologic and solid tumor cancers, as well as autoimmune diseases. By combining innovative science with a patient-centric vision, Acepodia aims to bring powerful, next-generation therapies to patients underserved by today’s treatments. For more information, please visit https://www.acepodia.com/.
Forward-Looking Statements
This press release contains forward-looking statements regarding the potential therapeutic benefits, evaluation outcomes, and future development strategies for the dual-payload BsAD2C program. Such statements are subject to risks and uncertainties that may cause actual results to differ materially. Neither Biocytogen nor Acepodia undertakes any obligation to update these forward-looking statements, whether as a result of new information, future events, or otherwise.
View source version on businesswire.com: https://www.businesswire.com/news/home/20250107874851/en/
Contacts
Media: pr@bbctg.com.cn
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
www.businesswire.com
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Objectway Expands Into the MENA Region by Signing With Kuwait Financial Centre "Markaz"9.1.2025 12:34:00 EET | Press release
Objectway enters the MENA region by signing its first client in Kuwait, Kuwait Financial Centre “Markaz”, a leading asset management and investment banking firm in the MENA region. This collaboration marks a significant milestone in Objectway's growth in the region. As a leading provider of innovative digital solutions for banks, asset managers, and wealth managers, Objectway will support Markaz in delivering an enhanced client experience for their clients, by significantly improving and automating processes and seamless client journeys. Markaz, established in 1974, is a prominent player in the financial sector in the MENA region, with total assets under management of over USD 4.56 billion, as of 30 September 2024, with bespoke advisory services and diversified investment portfolios, with a presence in 13 countries. Over the years, Markaz has pioneered innovation through the creation of various investment channels, which enjoy unique characteristics to help widen investors’ horizons an
Verne Appoints Michele Tagliatti as Chief Financial Officer9.1.2025 12:00:00 EET | Press release
Verne, a leading provider of sustainably powered HPC data centers across the Nordics, has announced the appointment of Michele Tagliatti as its Chief Financial Officer (CFO). With over 10 years of experience in the data center, telecommunications, and technology sectors, Tagliatti brings a wealth of knowledge to the role. He will focus on creating a results-based financial strategy that will be instrumental in driving Verne’s continued success as it scales its operations to meet the rising demand for cost-efficient, renewable-powered data center and colocation services for HPC and AI workloads. He will be based at Verne’s group headquarters in London. Before joining Verne, Tagliatti was at Liquid Intelligent Technologies, where he held several senior leadership roles, including Deputy Group Chief Financial Officer (DGCFO) and Group CFO of its data center business unit. During his tenure, he successfully led the financial restructuring and carve-out of the data center business unit, tha
Agile Data Engine Announces Built on Databricks Partner Status9.1.2025 11:15:00 EET | Press release
Agile Data Engine (ADE), provider of the all-in-one SaaS DataOps Development and Operations Platform for development, provision and operation of data lakehouses, has now been awarded Built on Partner status by Databricks, the Data and AI company. ADE has become a Nordic powerhouse for helping customers to move legacy data platforms to agile and resilient data lakehouses. The company offers accelerated tools that reduce implementation time and labor, helping businesses realize value more quickly by streamlining the complex process of data platform transformation and providing efficient development and operational capabilities for data lakehouses. The Databricks Data Intelligence Platform democratizes access to analytics and intelligent applications by marrying customers’ data with powerful AI models tuned to the unique characteristics of their business. The platform is built on a lakehouse foundation of open data formats and open governance to ensure that all data is completely within t
Infobip Recognized as AIT Fraud Prevention Leader by Juniper Research9.1.2025 11:01:00 EET | Press release
Global cloud communications platform Infobip has been recognized as the number one provider among Established Leaders in the Artificially Inflated Traffic (AIT) Fraud Prevention market by Juniper Research. The analyst firm has ranked Infobip first of 18 vendors in its Competitor Leaderboard for AIT Fraud Detection Solution Vendors 2024. Juniper Research scores vendors across 11 criteria, including but not limited to their size of operations in the AIT prevention market, the extent and breadth of relevant partnerships, market coverage, and product strength. Infobip scored highly across each of these and three further categories. Overall, Infobip was ranked as the Leading firm because it offers a comprehensive solution to AIT fraud detection and prevention strategies, including its ‘Infobip Signals’ solution, which detects AIT by monitoring phone number behavior, ranges, and types. Helping set Infobip aside from others in the market is its use of artificial intelligence (AI) and machine
European Commission Approves the Extension of the Indication of Palforzia® to the Treatment of Toddlers With Confirmed Peanut Allergy9.1.2025 10:00:00 EET | Press release
Stallergenes Greer, a biopharmaceutical company specialising in allergen immunotherapy (AIT), announces that the European Commission (EC) has approved the extension of indication of Palforzia® (defatted powder of Arachis hypogaea L., semen (peanut)) for thetreatment of toddlers (ages 1 through 3) with a confirmed diagnosis of peanut allergy. The marketing authorisation covers all 27 European member states and the three European Economic Area states (Iceland, Liechtenstein and Norway). This approval of the extension of indication of Palforzia® to toddlers, follows the July 2024 approval by the U.S. Food and Drug Administration (FDA). Palforzia® is the first and only EMA and FDA approved oral immunotherapy for toddlers with a confirmed diagnosis of peanut allergy. “Peanut allergy is one of the most frequent food allergies. Early intervention is crucial to reduce the risks of accidental exposure and may be very important in improving long-term outcomes. The approval of Palforzia for toddl
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom